• MEDIMABBIO

  • DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

  • 메인비주얼이미지

    MEDIMABBIO

  • 메인비주얼이미지
    DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

  • 메인비주얼이미지

    MEDIMABBIO

  • 메인비주얼이미지
    DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

SCROLL DOWN
About Us
about 이미지 about 이미지 about 이미지
MediMabBio is a ground-breaking biotherapeutic company focusing on the generation of novel immunotherapies for the treatment of cancer.

Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors.

The company has developed pipelines of highly promising novel drugs that aim to overcome the current limitations of cancer immunotherapy.

For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.

Pipeline
MMB pipeline addresses significant medically unmet needs in immuno-oncology by directly
targeting T cells, immune checkpoints and tumor micro-environment.
Product Indication Therapeutic Modality Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I
Oncology
MMB101 Immuno- Oncology Monoclonal Antibody
MMB102 Immuno- Oncology Monoclonal Antibody
MMB201 Immuno- Oncology Fusion Antibody
MMB202 Immuno- Oncology Fusion Antibody
Inflammatory Disease
MMB301 Autoimmune Disease Neutralizing Antibody
Infectious Disease
MMB401 Covid-19 Neutralizing Antibody
Product Indication Discovery Lead Optimization Preclinical
Efficacy
CMC Development
Oncology
MMB101 Immuno Oncology
MMB102 Immuno Oncology
MMB201 Immuno Oncology
MMB202 Immuno Oncology
Inflammatory Disease
MMB301 Autoimmune Disease
Infectious Disease
Covid-19 Autoimmune Disease
Product Discovery Lead
Optimization
Preclinical
Efficacy
CMC
Development
Oncology
MMB101
MMB102
MMB201
MMB202
Inflanmmatory Disease
MMB301
Infectious Disease
MMB401
Management
  • 여자 여자 여자
    Jennifer Yuhoi Kang, Ph.D Founder & Co-CEO
    EXPERIENCE
    • Samsung Bioepis
    • Samsung Advanced Institute of Technology
    • Harvard Medical School
    • University of Oxford
    EDUCATION University of Oxford (Biochemistry Ph.D) EXPERTISE Oncology, Infectious disease, lmmuno-oncology
    therapy, Vaccine development
  • 여자 여자 여자
    Hongseok Jo, Ph.D Founder & Co-CEO
    EXPERIENCE
    • Samsung Bioepis
    • Samsung Advanced Institute of Technology
    • KAIST
    EDUCATION KAIST (Bioscience Ph.D) EXPERTISE Biologics drug discovery and development,
    Oncology, Neurological disorder
Contact
Korea
  • MediMabBio Inc.
  • #721, 54, Changeop-ro, Sujeong-gu, Seongnam-si,
    Gyeonggi-do, Republic of Korea, 13449
  • info@medimabbio.com
  • 82-(0)31-623-2100
  • 82-(0)31-751-2101
United Kingdom
  • MediMab Biotherapeutics Ltd.
  • BioEscalator, the Innovation Building, the Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7FZ United Kingdom
  • infouk@medimabbio.com
  • 44-(0)20-7460-7899